The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Sanofi and Regeneron just scored their biggest new drug approval of the year—and for Sanofi, of the past several. Dupixent, also known as dupilumab, is now the first approved drug to inhibit the ...

The partners are currently studying Dupixent in a phase 3 COPD trial with 900 patients and plan to launch a second, confirmatory trial in the third quarter of 2020, Regeneron said. Sanofi will ...

In the first quarter of 2024, Dupixent generated global product sales of $3.09 billion (€2.84 billion), which were recorded by Sanofi, representing growth of 24.9% at a constant exchange rate.

Dupixent is Sanofi’s top-selling product. Across all of its approved indications, the drug accounted for more than €10.7 billion (about $11.6 billion) in global revenue last year, according to ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

Dupixent has become the key driver of the top line for Sanofi as well as Regeneron. In the first quarter of 2024, Dupixent generated global product sales of $3.09 billion (€2.84 billion), which ...